NovaBay Pharmaceuticals, Inc

(NYSE MKT:NBY)

Latest On NovaBay Pharmaceuticals, Inc (NBY):

Date/Time Type Description Signal Details
2023-05-11 22:40 ESTNewsNovaBay GAAP EPS of -$0.85 beats by $0.06, revenue of $3.12M misses by $0.08MN/A
2023-05-11 22:39 ESTNewsNovaBay Pharmaceuticals, Inc. (NBY) Q1 2023 Earnings Call TranscriptN/A
2023-04-28 09:17 ESTNewsNovaBay Pharmaceuticals down 18% on $3M convertible notes financingN/A
2023-04-21 11:02 ESTNewsNovaBay surges ~20% on launch of DERMAdoctor psoriasis cream on QVCN/A
2023-03-31 08:01 ESTNewsNovaBay Pharmaceuticals, Inc. (NBY) Q4 2022 Earnings Call TranscriptN/A
2023-03-30 07:38 ESTNewsNovaBay Q4 2022 Earnings PreviewN/A
2023-03-07 22:21 ESTNewsNovaBay Pharma gains 10% on launch of new oral supplement to comfort dry eyesN/A
2022-11-15 22:34 ESTNewsNovaBay Pharma announces 1-for-35 reverse stock splitN/A
2022-11-15 05:25 ESTNewsNovaBay GAAP EPS of -$0.10, revenue of $3.83MN/A
2022-11-15 05:25 ESTNewsNovaBay Pharmaceuticals, Inc. (NBY) Q3 2022 Earnings Call TranscriptN/A
2022-11-10 03:26 ESTNewsNovaBay Q3 2022 Earnings PreviewN/A
2022-10-18 21:47 ESTNewsNovaBay stock rises on orders for Kakadu anti-aging serumN/A
2022-10-07 19:08 ESTNewsNovaBay Pharma receives non-compliance letter from NYSEN/A
2022-09-10 01:25 ESTNewsNovaBay Pharma enters into agreements for private placement and warrant reprice transactions to raise up to $5.3MN/A
2022-08-12 05:39 ESTNewsNovaBay GAAP EPS of -$0.04 in-line, revenue of $3.04M misses by $0.47MN/A
2022-08-12 05:38 ESTNewsNovaBay Pharmaceuticals, Inc. (NBY) CEO Justin Hall on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-10 20:50 ESTNewsNovaBay Q2 2022 Earnings PreviewN/A
2022-07-15 17:05 ESTNewsNovaBay Pharma reports record Avenova sales during Amazon’s Prime Day eventN/A
2022-05-12 21:21 ESTNewsNovaBay GAAP EPS of $0.00 beats by $0.03, revenue of $2.63M misses by $0.63MN/A
2022-05-12 21:20 ESTNewsNovaBay Pharmaceuticals, Inc. (NBY) CEO Justin Hall on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-09 13:53 ESTNewsNovaBay introduces new skincare products with anti-aging formulationsN/A
2022-03-30 21:27 ESTNewsNovaBay Pharma down on Q4 revenue missN/A
2022-03-30 04:50 ESTNewsNovaBay GAAP EPS of -$0.02 beats by $0.03, revenue of $2.64M misses by $0.71MN/A
2022-03-30 04:50 ESTNewsNovaBay Pharmaceuticals, Inc. (NBY) CEO Justin Hall on Q4 2021 Results - Earnings Call TranscriptN/A
2022-03-29 05:59 ESTNewsNovaBay Q4 2021 Earnings PreviewN/A
2022-03-09 10:09 ESTNewsNovaBay stock rises 14% on launch of HA SerumN/A
2022-02-23 22:41 ESTNewsNovaBay engages marketing firm for DERMAdoctor skincare products in ChinaN/A
2021-11-13 01:14 ESTNewsNovaBay Pharmaceuticals' (NBY) CEO Justin Hall on Q3 2021 Results - Earnings Call TranscriptN/A
2021-11-12 05:32 ESTNewsNovaBay EPS misses by $0.01, misses on revenueN/A
2021-10-15 18:05 ESTNewsWarning: NBY is at high risk of performing badlyN/A
2021-10-07 15:49 ESTNewsNBY is at high risk of performing badlyN/A
2021-09-30 19:17 ESTNewsNovaBay DERMAdoctor Transaction CallN/A
2021-09-30 19:17 ESTNewsNovaBay Pharmaceuticals, Inc. (NBY) CEO Justin Hall on DERMAdoctor Acquisition - Conference Call TranscriptN/A
2021-08-13 17:50 ESTNewsNovaBay Pharmaceuticals, Inc. (NBY) CEO Justin Hall on Q2 2021 Results - Earnings Call TranscriptN/A
2021-08-12 21:21 ESTNewsNovaBay EPS in-line, beats on revenueN/A
2021-07-21 16:24 ESTNewsNovaBay partners with Imprimisrx to promote prescription AvenovaN/A
2021-03-26 12:51 ESTNewsNovaBay Pharmaceuticals' (NBY) CEO Justin Hall on Q4 2020 Results - Earnings Call TranscriptN/A
2021-03-25 18:02 ESTNewsNovaBay EPS in-line, misses on revenueN/A
2021-02-10 15:36 ESTNewsNovaBay reassures investors of liquidity levelN/A
2021-01-06 16:16 ESTFinancialsCompany financials have been released.Neutral
2020-11-26 20:56 ESTFinancialsCompany financials have been released.Neutral
2020-11-23 23:16 ESTNewsNovaBay Pharma rises 8% on Avenova distribution deal in AustraliaN/A
2020-11-18 12:42 ESTFinancialsCompany financials have been released.Neutral
2020-11-17 20:36 ESTAnalyst RatingThe Analyst Target Price has increased from $2.5 to $2.63.Buy
2020-11-13 12:47 ESTEarnings EstimateAn EPS average of -$0.04 is estimated for the quarter ending on March 31, 2021.Buy
2020-11-13 04:48 ESTNewsNovaBay EPS misses by $0.04, misses on revenueN/A
2020-11-13 04:47 ESTNewsNovaBay Pharmaceuticals, Inc. (NBY) CEO Justin Hall on Q3 2020 Results - Earnings Call TranscriptN/A
2020-11-07 16:34 ESTFinancialsCompany financials have been released.Neutral
2020-10-12 11:19 ESTNewsNovaBay +3.6% on regaining compliance with NYSE standardsN/A
2020-09-26 13:30 ESTFinancialsCompany financials have been released.Neutral

About NovaBay Pharmaceuticals, Inc (NBY):

NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes non-antibiotic anti-infective products to address therapeutic needs of the anti-infective market in the United States and internationally. The company offers Avenova, a solution for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye, including the eyelid; CelleRx for the aesthetic dermatology market; and NeutroPhase for the wound care market. It also develops auriclosene, a synthetic molecule for use against bacteria, viruses, and fungi. The company has a collaboration and license agreement with Virbac to develop auriclosene for veterinary markets for companion animals. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.

NBY Quotes by TradingView

See Advanced Chart

General

  • Name NovaBay Pharmaceuticals, Inc
  • Symbol NBY
  • Type Common Stock
  • Exchange NYSE MKT
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 26
  • Last Split Factor1:25
  • Last Split Date2015-12-21
  • Fiscal Year EndDecember
  • IPO Date2007-10-26
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryPharmaceuticals
  • Gic SubIndustryPharmaceuticals
  • Web URLhttp://www.novabay.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 3.38
  • Price/Book (Most Recent Quarter) 3.16
  • Enterprise Value Revenue 3.2
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Next Quarter EPS Estimate -$0.03
  • Profit Margin -122%
  • Operating Margin -69%
  • Return on Assets -27%
  • Return on Equity -138%
  • Revenue 9.79 million
  • Earnings Per Share -$0.58
  • Revenue Per Share $0.31
  • Gross Profit 4.86 million
  • Quarterly Earnings Growth 34.4%
View More

Highlights

  • Market Capitalization 42.62 million
  • EBITDA -8698000
  • Analyst Target Price $2.63
  • Book Value Per Share $0.33
View More

Share Statistics

  • Shares Outstanding 41.78 million
  • Shares Float 34.53 million
  • % Held by Insiders 2521%
  • % Held by Institutions 6.21%
  • Shares Short 666402
  • Shares Short Prior Month 1.11 million
  • Short Ratio 0.08
  • Short % of Float 2%
  • Short % of Shares Outstanding 2%
View More

Technicals

  • Beta 3.72
  • 52 Week High $1.64
  • 52 Week Low $0.52
  • 50 Day Moving Average 1.08
  • 200 Day Moving Average 0.82
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

NovaBay Pharmaceuticals, Inc (NBY) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

NovaBay Pharmaceuticals, Inc (NBY) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-09-302020-11-12$N/A-$0.04-$0.04-2%
2020-06-302020-08-06$N/A-$0.02-$0.0661%
2020-03-312020-05-07$1.89 million-$0.06-$0.0712.14%
2019-12-312020-03-26$1.7 million-$0.12-$0.08-49.25%
2019-09-302019-11-07$1.62 million-$0.11-$0.09-17%
2019-06-302019-08-07$1.79 million-$0.10-$0.105%
2019-03-312019-05-09$1.49 million-$0.24-$0.12-110.87%
2018-12-312019-03-28$3.63 million-$0.09-$0.06-70.91%
2018-09-302018-11-14$3.14 million-$0.11-$0.116.13%
2018-06-302018-08-07$2.79 million-$0.09-$0.1225%
2018-03-312018-05-10$2.95 million-$0.13-$0.08-73.33%
2017-12-312018-03-20$6.32 million$0.02-$0.05140%
2017-09-302017-11-14$4.09 million-$0.16-$0.09-77.78%
2017-06-302017-08-10$4.12 million-$0.11-$0.126.38%
2017-03-312017-05-11$3.7 million-$0.26-$0.15-73.33%
2016-12-312017-03-23$4.08 million-$0.11-$0.07-57.14%
2016-09-302016-11-10$3.44 million-$0.34-$0.16-112.5%
2016-06-302016-08-11$2.66 million-$0.36-$0.5938.98%
2016-03-312016-05-12$1.72 million-$1.24-$0.73-69.86%
2015-12-312016-03-03$1.64 million-$1.26-$1.388.36%
2015-09-302015-11-16$1.2 million-$1.75-$1.750%
2015-06-302015-08-13$1.01 million-$1.75-$1.750%
2015-03-312015-05-14$538000-$2.25-$1.50-50%
2014-12-312015-03-26$679000-$2.25-$1.75-28.57%
2014-09-302014-11-12$152000-$2.00-$2.125.66%
2014-06-302014-07-31$123000-$1.50-$2.2533.33%
2014-03-312014-05-01$100000-$2.00-$2.7527.27%
2013-12-312014-03-06$287000-$2.50-$1.87-33.69%
2013-09-302013-11-14$1.1 million-$2.50-$2.500%
2013-06-302013-08-01$848000-$2.75-$2.50-10%
2013-03-312013-05-02$1.02 million-$2.75-$1.75-57.14%
2012-12-312013-03-14$1.11 million-$1.75-$2.2522.22%
2012-09-302012-11-01$3.64 million$0.07-$1.00106.83%
2012-06-302012-08-09$871000-$2.00-$2.000%
2012-03-312012-05-04$1.32 million-$2.25-$1.75-28.57%
2011-12-312012-03-27$1.23 million-$3.52
2011-09-302011-11-07$2.77 million-$0.25-$2.2588.89%
2011-06-302011-08-10$4.53 million$0.50-$2.37121.1%
2011-03-312011-05-16$2.49 million-$2.00-$1.25-60%
2010-12-312011-03-10$3.04 million$0.25-$0.62140.32%
2010-09-302010-11-12$2.09 million-$1.75-$1.876.42%
2010-06-302010-08-12$2.55 million-$1.25-$2.0037.5%
2010-03-312010-05-12$2.08 million-$1.75-$1.928.85%
2009-12-312010-03-30$7.49 million$3.50-$0.42933.33%
2009-09-302009-11-13$3.22 million-$0.12-$0.2552.24%
2009-06-302009-08-14$2.36 million-$0.25-$2.3789.45%
2009-03-312009-05-18$2.61 million-$0.25-$2.2588.89%
2008-12-312009-03-31$2.2 million-$1.75-$2.3324.89%
2008-09-302008-11-14$1.59 million-$1.75-$3.3748.07%
2008-06-302008-08-14$1.44 million-$2.75-$3.3317.42%
2008-03-312008-05-14$1.49 million-$3.25-$1.75-85.71%
2007-12-312008-03-11$1.52 million-$2.25-$1.75-28.57%
2007-09-302007-11-16$1.44 million-$2.40

NovaBay Pharmaceuticals, Inc (NBY) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

NovaBay Pharmaceuticals, Inc (NBY) Chart:

NovaBay Pharmaceuticals, Inc (NBY) News:

Below you will find a list of latest news for NovaBay Pharmaceuticals, Inc (NBY) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

NovaBay Pharmaceuticals, Inc (NBY) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Latest NBY Trades:

Date Shares Price
Jun 13, 2022 5:55 PM EST100$0.22

NovaBay Pharmaceuticals, Inc (NBY) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1389545/000143774920013082/0001437749-20-013082-index.htm
2019-04-09UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1389545/000000000019006842/0000000000-19-006842-index.htm
2019-07-29UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1389545/000000000019011702/0000000000-19-011702-index.htm
2019-09-10UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1389545/000000000019013384/0000000000-19-013384-index.htm
2019-11-01UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1389545/000000000019015069/0000000000-19-015069-index.htm
2020-05-20UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1389545/000000000020004513/0000000000-20-004513-index.htm
2020-08-27UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1389545/000000000020008098/0000000000-20-008098-index.htm
2019-08-15SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1389545/000090266419003417/0000902664-19-003417-index.htm
2020-01-23SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1389545/000090266420000408/0000902664-20-000408-index.htm
2019-08-19SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1389545/000091957419005493/0000919574-19-005493-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1389545/000091957420001595/0000919574-20-001595-index.htm
2018-06-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1389545/000143774918011211/0001437749-18-011211-index.htm
2018-06-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1389545/000143774918011213/0001437749-18-011213-index.htm
2018-06-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1389545/000143774918011214/0001437749-18-011214-index.htm
2018-06-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1389545/000143774918011215/0001437749-18-011215-index.htm
2018-08-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1389545/000143774918014739/0001437749-18-014739-index.htm
2018-09-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1389545/000143774918017596/0001437749-18-017596-index.htm
2018-10-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1389545/000143774918018182/0001437749-18-018182-index.htm
2018-10-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1389545/000143774918018183/0001437749-18-018183-index.htm
2018-11-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1389545/000143774918020822/0001437749-18-020822-index.htm
2019-03-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1389545/000143774919003783/0001437749-19-003783-index.htm
2019-03-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1389545/000143774919004563/0001437749-19-004563-index.htm
2019-03-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1389545/000143774919004683/0001437749-19-004683-index.htm
2019-03-263Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1389545/000143774919005675/0001437749-19-005675-index.htm
2019-03-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1389545/000143774919005842/0001437749-19-005842-index.htm
2019-03-2910-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1389545/000143774919006017/0001437749-19-006017-index.htm
2019-04-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1389545/000143774919006128/0001437749-19-006128-index.htm
2019-04-01S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1389545/000143774919006266/0001437749-19-006266-index.htm
2019-04-10CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1389545/000143774919006835/0001437749-19-006835-index.htm
2019-04-1210-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1389545/000143774919007095/0001437749-19-007095-index.htm
2019-04-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1389545/000143774919007182/0001437749-19-007182-index.htm
2019-04-16SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1389545/000143774919007309/0001437749-19-007309-index.htm
2019-04-16SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1389545/000143774919007310/0001437749-19-007310-index.htm
2019-04-19DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1389545/000143774919007618/0001437749-19-007618-index.htm
2019-04-19DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1389545/000143774919007619/0001437749-19-007619-index.htm
2019-05-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1389545/000143774919008714/0001437749-19-008714-index.htm
2019-05-03DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1389545/000143774919008722/0001437749-19-008722-index.htm
2019-05-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1389545/000143774919009663/0001437749-19-009663-index.htm
2019-05-1510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1389545/000143774919010029/0001437749-19-010029-index.htm
2019-05-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1389545/000143774919010591/0001437749-19-010591-index.htm
2019-06-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1389545/000143774919011273/0001437749-19-011273-index.htm
2019-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1389545/000143774919011905/0001437749-19-011905-index.htm
2019-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1389545/000143774919011906/0001437749-19-011906-index.htm
2019-06-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1389545/000143774919011909/0001437749-19-011909-index.htm
2019-06-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1389545/000143774919012009/0001437749-19-012009-index.htm
2019-06-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1389545/000143774919012010/0001437749-19-012010-index.htm
2019-06-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1389545/000143774919012150/0001437749-19-012150-index.htm
2019-06-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1389545/000143774919012241/0001437749-19-012241-index.htm
2019-06-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1389545/000143774919012813/0001437749-19-012813-index.htm
2019-07-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1389545/000143774919013120/0001437749-19-013120-index.htm
2019-07-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1389545/000143774919013933/0001437749-19-013933-index.htm
2019-07-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1389545/000143774919014663/0001437749-19-014663-index.htm
2019-07-26S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1389545/000143774919014744/0001437749-19-014744-index.htm
2019-07-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1389545/000143774919014757/0001437749-19-014757-index.htm
2019-07-29CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1389545/000143774919014843/0001437749-19-014843-index.htm
2019-08-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1389545/000143774919015525/0001437749-19-015525-index.htm
2019-08-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1389545/000143774919015688/0001437749-19-015688-index.htm
2019-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1389545/000143774919015693/0001437749-19-015693-index.htm
2019-08-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1389545/000143774919016153/0001437749-19-016153-index.htm
2019-08-09424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1389545/000143774919016256/0001437749-19-016256-index.htm
2019-08-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1389545/000143774919016569/0001437749-19-016569-index.htm
2019-08-30PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1389545/000143774919017705/0001437749-19-017705-index.htm
2019-09-04S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1389545/000143774919017882/0001437749-19-017882-index.htm
2019-09-11CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1389545/000143774919018175/0001437749-19-018175-index.htm
2019-09-13DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1389545/000143774919018344/0001437749-19-018344-index.htm
2019-09-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1389545/000143774919018484/0001437749-19-018484-index.htm
2019-09-303Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1389545/000143774919019296/0001437749-19-019296-index.htm
2019-10-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1389545/000143774919019917/0001437749-19-019917-index.htm
2019-10-25S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1389545/000143774919020651/0001437749-19-020651-index.htm
2019-10-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1389545/000143774919020738/0001437749-19-020738-index.htm
2019-10-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1389545/000143774919020739/0001437749-19-020739-index.htm
2019-10-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1389545/000143774919020740/0001437749-19-020740-index.htm
2019-10-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1389545/000143774919020741/0001437749-19-020741-index.htm
2019-10-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1389545/000143774919020742/0001437749-19-020742-index.htm
2019-10-284/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1389545/000143774919020744/0001437749-19-020744-index.htm
2019-10-284/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1389545/000143774919020745/0001437749-19-020745-index.htm
2019-10-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1389545/000143774919020935/0001437749-19-020935-index.htm
2019-11-01CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1389545/000143774919021135/0001437749-19-021135-index.htm
2019-11-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1389545/000143774919021963/0001437749-19-021963-index.htm
2019-12-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1389545/000143774919024639/0001437749-19-024639-index.htm
2019-12-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1389545/000143774919024720/0001437749-19-024720-index.htm
2020-01-283Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1389545/000143774920001311/0001437749-20-001311-index.htm
2020-02-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1389545/000143774920001861/0001437749-20-001861-index.htm
2020-02-06POS AMPost-Effective amendments for registration statementhttps://www.sec.gov/Archives/edgar/data/1389545/000143774920001911/0001437749-20-001911-index.htm
2020-02-07S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1389545/000143774920002052/0001437749-20-002052-index.htm
2020-03-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1389545/000143774920005328/0001437749-20-005328-index.htm
2020-03-193Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1389545/000143774920005693/0001437749-20-005693-index.htm
2020-03-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1389545/000143774920005779/0001437749-20-005779-index.htm
2020-03-2610-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1389545/000143774920006213/0001437749-20-006213-index.htm
2020-04-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1389545/000143774920007137/0001437749-20-007137-index.htm
2020-04-03PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1389545/000143774920007154/0001437749-20-007154-index.htm
2020-04-15DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1389545/000143774920007773/0001437749-20-007773-index.htm
2020-04-15DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1389545/000143774920007779/0001437749-20-007779-index.htm
2020-04-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1389545/000143774920007996/0001437749-20-007996-index.htm
2020-04-27424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1389545/000143774920008585/0001437749-20-008585-index.htm
2020-04-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1389545/000143774920008587/0001437749-20-008587-index.htm
2020-05-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1389545/000143774920009347/0001437749-20-009347-index.htm
2020-05-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1389545/000143774920009458/0001437749-20-009458-index.htm
2020-05-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1389545/000143774920009821/0001437749-20-009821-index.htm
2020-05-133Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1389545/000143774920010592/0001437749-20-010592-index.htm
2020-05-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1389545/000143774920010665/0001437749-20-010665-index.htm
2020-05-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1389545/000143774920011005/0001437749-20-011005-index.htm
2020-05-15S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1389545/000143774920011044/0001437749-20-011044-index.htm
2020-05-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1389545/000143774920011168/0001437749-20-011168-index.htm
2020-05-20CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1389545/000143774920011359/0001437749-20-011359-index.htm
2020-05-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1389545/000143774920011939/0001437749-20-011939-index.htm
2020-05-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1389545/000143774920012072/0001437749-20-012072-index.htm
2020-05-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1389545/000143774920012073/0001437749-20-012073-index.htm
2020-05-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1389545/000143774920012074/0001437749-20-012074-index.htm
2020-05-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1389545/000143774920012075/0001437749-20-012075-index.htm
2020-05-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1389545/000143774920012076/0001437749-20-012076-index.htm
2020-05-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1389545/000143774920012077/0001437749-20-012077-index.htm
2020-06-15424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1389545/000143774920013080/0001437749-20-013080-index.htm
2020-06-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1389545/000143774920013082/0001437749-20-013082-index.htm
2020-07-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1389545/000143774920015464/0001437749-20-015464-index.htm
2020-07-21424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1389545/000143774920015466/0001437749-20-015466-index.htm
2020-08-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1389545/000143774920016531/0001437749-20-016531-index.htm
2020-08-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1389545/000143774920016868/0001437749-20-016868-index.htm
2020-08-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1389545/000143774920018340/0001437749-20-018340-index.htm
2020-08-21S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1389545/000143774920018527/0001437749-20-018527-index.htm
2020-08-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1389545/000143774920018601/0001437749-20-018601-index.htm
2020-08-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1389545/000143774920018606/0001437749-20-018606-index.htm
2020-08-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1389545/000143774920018607/0001437749-20-018607-index.htm
2020-08-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1389545/000143774920018608/0001437749-20-018608-index.htm
2020-08-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1389545/000143774920018610/0001437749-20-018610-index.htm
2020-08-24SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1389545/000143774920018617/0001437749-20-018617-index.htm
2020-08-28CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1389545/000143774920018881/0001437749-20-018881-index.htm
2020-09-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1389545/000143774920019532/0001437749-20-019532-index.htm
2020-10-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1389545/000143774920021043/0001437749-20-021043-index.htm
2020-05-01DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1389545/000155361020000003/0001553610-20-000003-index.htm
2020-05-22DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1389545/000155361020000004/0001553610-20-000004-index.htm
2019-07-03DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1389545/000178110919000001/0001781109-19-000001-index.htm
2019-08-26DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1389545/000178395419000001/0001783954-19-000001-index.htm
2019-08-26DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1389545/000178395419000002/0001783954-19-000002-index.htm
2020-07-31DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1389545/000181971020000002/0001819710-20-000002-index.htm
2019-04-12EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1389545/999999999519000700/9999999995-19-000700-index.htm
2019-07-31EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1389545/999999999519001772/9999999995-19-001772-index.htm
2019-09-12EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1389545/999999999519002084/9999999995-19-002084-index.htm
2019-11-05EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1389545/999999999519002485/9999999995-19-002485-index.htm
2020-02-10EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1389545/999999999520000297/9999999995-20-000297-index.htm
2020-05-22EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1389545/999999999520001245/9999999995-20-001245-index.htm
2020-09-01EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1389545/999999999520002335/9999999995-20-002335-index.htm
2019-03-11SEC STAFF SEC Staff Action: ORDERhttps://www.sec.gov/Archives/edgar/data/1389545/999999999719000958/9999999997-19-000958-index.htm

NovaBay Pharmaceuticals, Inc (NBY) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of NovaBay Pharmaceuticals, Inc (NBY). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 2521%
Institutional Ownership: 621%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2019-06-10MIJIA WUDirectorSell47,619.002.0396,666.570.00https://www.sec.gov/Archives/edgar/data/1389545/000143774919011909/0001437749-19-011909-index.htm
2019-06-11MIJIA WUDirectorSell15,873.004.0464,126.920.00https://www.sec.gov/Archives/edgar/data/1389545/000143774919011909/0001437749-19-011909-index.htm
2020-08-17MIJIA WUDirectorSell20,000.001.3527,000.000.00https://www.sec.gov/Archives/edgar/data/1389545/000143774920018340/0001437749-20-018340-index.htm
2019-07-30MARK M SIECZKAREKInsiderBuy167,938.001,156,883.00https://www.sec.gov/Archives/edgar/data/1389545/000143774919015525/0001437749-19-015525-index.htm
2020-08-17MIJIA WUDirectorBuy20,000.000.306,000.0020,000.00https://www.sec.gov/Archives/edgar/data/1389545/000143774920018340/0001437749-20-018340-index.htm
2020-08-01Jian Ping Fu10% Share HolderSell1,302,350.001.231,601,890.504,000,000.00https://www.sec.gov/Archives/edgar/data/1389545/000143774920016531/0001437749-20-016531-index.htm
2019-06-11Pharma (Hong Kong) Co Ltd Pioneer10% Share HolderSell24,326.004.0498,277.045,188,421.00https://www.sec.gov/Archives/edgar/data/1389545/000143774919012009/0001437749-19-012009-index.htm
2019-06-11Jian Ping Fu10% Share HolderSell380,954.003.841,462,863.365,302,350.00https://www.sec.gov/Archives/edgar/data/1389545/000143774919012010/0001437749-19-012010-index.htm